Neurodevelopmental Effect of Acetaminophen Exposures
对乙酰氨基酚暴露对神经发育的影响
基本信息
- 批准号:10736409
- 负责人:
- 金额:$ 53.04万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-15 至 2027-05-31
- 项目状态:未结题
- 来源:
- 关键词:AcetaminophenAddressAdolescenceAdverse effectsAffectAgeAminophenolsAnalgesic and AntipyreticAsiaAttention deficit hyperactivity disorderBehavioralBirthBrainChildChildhoodClinical TrialsCohort StudiesConsumptionDataData SourcesDatabasesDecision MakingDevelopmentDiagnosisDiseaseDoseEnrollmentEthicsEuropeExposure toFetal DevelopmentFetal GrowthFetusFeverGenetic RiskGuidelinesHealthIntakeInterviewInvestigationJointsKnowledgeLifeLinkLiteratureMaternal-fetal medicineMedicalMental HealthModelingMothersMotorObservational StudyOutcomePerformancePersonsPharmaceutical PreparationsPharmacoepidemiologyPhenotypePolicy MakingPolypharmacyPopulationPregnancyPropertyProspective, cohort studyRandomizedRecommendationRecordsRegistriesReportingResearchResearch DesignResearch Project GrantsReview LiteratureRiskRoleSafetySamplingSchoolsSocietiesSymptomsSystematic BiasTimeUnited States Food and Drug Administrationandrogeniccognitive functioncohortcraniofacialearly life exposureexecutive functionexperienceexperimental studyfetalinfancymaternal serummultidisciplinaryneurobehaviorneurobehavioral disorderneurodevelopmentneurodevelopmental effectneuropsychiatryoffspringpain reductionpostnatalpregnantprenatalprenatal exposureprenatal influenceprospectivetime interval
项目摘要
Project Summary
Acetaminophen (N-acetyl-p-aminophenol or APAP) is recommended as a safe treatment to reduce pain and
fever during pregnancy. An estimated 45-65% of pregnant people reported intake of APAP in the U.S., but there
has been little data on safety for potential health effects in the prenatally exposed offspring. APAP
placental
can cross the
barrier reaching the fetus which has limited capacity to metabolize the compound in early development.
Recent experimental studies demonstrated compelling evidence suggesting APAP can induce anti-androgenic
effects potentially affecting fetal brain development. The Society for Maternal-Fetal Medicine and the U.S. Food
and Drug Administration have called for a more thorough investigation and better data to guide the safety of
APAP use in pregnancy. Our experienced and multidisciplinary team proposes to leverage the rich data collected
in the Danish National Birth Cohort (DNBC) and records from the Danish population medical registries to
investigate the potential effects of APAP exposures on fetal development. In Aim 1, we will study 64,322 mother-
child pairs enrolled in the DNBC and investigate the effects of prenatal exposure to APAP on a wide spectrum
of neurodevelopmental outcomes, ascertained at multiple time points from infancy through age 18. Six domains
of outcomes will be examined, including milestones in infancy, craniofacial markers, neurobehavioral disorders,
motor function, school performance, and mental health. A rich set of confounding factors, including maternal
illnesses and familial/genetic risks, will be examined in a robust multi-stage analytical framework. In addition, we
will evaluate the effect of post-natal APAP exposure on neurodevelopment (aim 1a), the effect of APAP
exposures on childhood ADHD, adjusting for the genetic risk of ADHD (aim 1b), and explore whether APAP
exposures affect distinct neuropsychiatric phenotypes and/or behavioral trajectories across childhood and
adolescence (aim 1c). In Aim 2, we will investigate the influence of prenatal co-medication exposures with APAP
and their impacts on neurodevelopment. We will examine whether medications that co-occur with APAP use
during pregnancy confound the associations between APAP exposure and child neurodevelopment. We will also
examine the joint effects of co-medications exposures. We will focus on a list of common medications (7 major
and 15 subclasses) that impact fetal growth and/or brain development documented in the literature. This timely
research project will provide strong and scientifically rigorous data to inform long-term health effects of early life
exposure to APAP on child neurodevelopment. This is also the most extensive cohort study investigating
maternal polypharmacy exposure effects on offspring neurodevelopment. Our findings will contribute to
regulatory recommendations and policymaking decisions for APAP, a widely consumed medication in pregnancy,
as well as related co-medication use.
项目摘要
醋氨酚(N-乙酰-对氨基酚或APAP)被推荐为一种安全的治疗方法,以减轻疼痛和
怀孕期间发烧。据估计,在美国有45%-65%的孕妇报告摄入了APAP,但
在产前暴露的后代中,关于潜在健康影响的安全性的数据很少。APAP
胎盘
可以跨过
到达胎儿的屏障,在发育早期代谢化合物的能力有限。
最近的实验研究表明,令人信服的证据表明,APAP可以诱导抗雄激素
可能影响胎儿大脑发育的因素。母胎医学学会与美国食品
和药品监督管理局呼吁进行更彻底的调查和更好的数据来指导
APAP在妊娠中的应用。我们经验丰富的多学科团队建议利用收集到的丰富数据
在丹麦国家出生队列(DNBC)和丹麦人口医疗登记处的记录中
研究APAP暴露对胎儿发育的潜在影响。在目标1中,我们将研究64,322名母亲-
在DNBC登记的儿童对,并调查产前暴露于APAP的广泛影响
从婴儿期到18岁,在多个时间点确定的神经发育结果。
包括婴儿期的里程碑、颅面标志、神经行为障碍、
运动功能、学习成绩和心理健康。一组丰富的混杂因素,包括母体
将在一个强有力的多阶段分析框架中对疾病和家族/遗传风险进行审查。此外,我们
将评估出生后暴露于APAP对神经发育的影响(目标1a),APAP的影响
儿童ADHD的暴露,调整ADHD的遗传风险(目标1b),并探索APAP是否
暴露会影响儿童和青少年不同的神经精神表型和/或行为轨迹
青春期(目标1c)。在目标2中,我们将调查产前联合用药暴露对APAP的影响。
以及它们对神经发育的影响。我们将检查与APAP同时发生的药物是否使用
在怀孕期间,APAP暴露与儿童神经发育之间的联系被混淆。我们还将
检查联合用药暴露的联合影响。我们将重点介绍常见药物的清单(7种主要药物
和15个子类),影响文献中记载的胎儿生长和/或脑发育。这来得正是时候
研究项目将提供强有力和科学严谨的数据,以告知早期生活对长期健康的影响
暴露于APAP对儿童神经发育的影响。这也是最广泛的队列研究调查
母亲接触多种药物对子代神经发育的影响。我们的发现将有助于
APAP是一种广泛使用的妊娠期药物,其监管建议和政策决策
以及相关的联合用药。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Zeyan Liew其他文献
Zeyan Liew的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Zeyan Liew', 18)}}的其他基金
Paternal and Maternal Perfluoroalkyl Substance Exposure and Offspring health
父亲和母亲全氟烷基物质暴露与后代健康
- 批准号:
10287991 - 财政年份:2021
- 资助金额:
$ 53.04万 - 项目类别:
Neurodevelopmental Effects of Perfluorinated Chemicals
全氟化学品对神经发育的影响
- 批准号:
9789884 - 财政年份:2018
- 资助金额:
$ 53.04万 - 项目类别:
Neurodevelopmental effects of Perfluorinated Chemicals
全氟化学品对神经发育的影响
- 批准号:
9243107 - 财政年份:2017
- 资助金额:
$ 53.04万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 53.04万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 53.04万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 53.04万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 53.04万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 53.04万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 53.04万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 53.04万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 53.04万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 53.04万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 53.04万 - 项目类别:
Research Grant